A major advantage of using a cytokine adjuvant, like GM-CSF, is the ability to boost the immunogenicity of a single dose of vaccine. During the COVID-19 pandemic, people were required... read more →
T cells are typically known to provide effective natural defense against infection and diseases. However, in cases where disease develops due to naturally occurring mutations in the body, like autoimmune... read more →
All vaccines are known to have some level of waning immunity. The extent to which vaccine efficacy decreases is impacted by many factors, such as the characteristics of the infectious... read more →
On June 25, 2025, FDA approves required updated warning in labeling of mRNA COVID-19 vaccines regarding myocarditis and pericarditis (following vaccination). Combined Therapeutics has developed one potential solution to the... read more →
mRNA vaccines have transformed medicine — but they also face real challenges: off-target expression in vital organs, safety concerns, and recent public criticism questioning their durability and risk profile. At... read more →
Combined Therapeutics has designed a flexible and versatile Multi-Organ Protection (MOP) Platform that utilizes miRNA binding sites in the 3’ UTR of mRNA to reduce off target protein expression for... read more →